Narinder Singh

Narinder joined Arcellx in Oct 2021 and serves as the chief Technical officer. Narinder has Over two decades of technical and operational leadership experience in end-to-end biopharmaceutical clinical development, commercialization, and life cycle management. Previously, Narinder was CTO for Forte Biosciences, and prior to Forte, he served as EVP Technical Operations at Aimmune Inc. Prior to Aimmune, Narinder led neoantigen-based personalized cancer vaccine and T cell therapy development as SVP, Pharmaceutical Sciences and Manufacturing at Genocea. Prior to Genocea, Narinder served in a variety of technical leadership roles in drug product and combination device development, commercialization, and manufacturing operations at Momenta Pharmaceuticals d Amgen. Narinder holds a B.Tech/M.Tech in Biochemical Engineering and Biotechnology from the Indian Institute of Technology, Delhi, an MS in Chemical Engineering from the University of Houston, and an MBA from the UCLA Anderson School of Management.